Heartland Express Declares Quarterly Dividend of $0.02 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy HTLD?
Source: seekingalpha
- Quarterly Dividend Announcement: Heartland Express has declared a quarterly dividend of $0.02 per share, maintaining consistency with previous distributions, which demonstrates the company's ongoing ability to generate stable cash flow.
- Dividend Yield: The forward yield of 0.84% reflects the company's shareholder return strategy in the current market environment, indicating that while the yield is relatively low, it still attracts income-seeking investors.
- Shareholder Record Dates: The dividend will be payable on April 3, with a record date of March 24 and an ex-dividend date also on March 24, ensuring shareholders receive their dividends in a timely manner.
- Market Reaction Analysis: Although the dividend announcement did not significantly boost the stock price, the selling pressure on Heartland Express is viewed as logical, as the stock has reached a fully priced level, reflecting investor caution regarding future returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HTLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HTLD
Wall Street analysts forecast HTLD stock price to fall
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 9.530
Low
8.00
Averages
9.33
High
12.00
Current: 9.530
Low
8.00
Averages
9.33
High
12.00
About HTLD
Heartland Express, Inc. is a holding company. The Company, together with its subsidiaries, is a short, medium and long-haul truckload carrier and transportation services provider. It primarily provides a nationwide asset-based dry van truckload service for various shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The Company’s primary customers include retailers, manufacturers and parcel carriers. Its over-the-road tractors are equipped with mobile communication systems. It operates 28 terminal facilities throughout the contiguous United States and one in Mexico. The Company’s subsidiaries include Heartland Express, Inc. of Iowa, Heartland Express Services, Inc., Heartland Express Maintenance Services, Inc., Midwest Holding Group, LLC, Millis Transfer, LLC, Smith Transport, Inc., Transportation Resources, Inc., Contract Freighters, Inc., and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Heartland Express Declares Quarterly Dividend of $0.02 per Share
- Quarterly Dividend Announcement: Heartland Express has declared a quarterly dividend of $0.02 per share, maintaining consistency with previous distributions, which demonstrates the company's ongoing ability to generate stable cash flow.
- Dividend Yield: The forward yield of 0.84% reflects the company's shareholder return strategy in the current market environment, indicating that while the yield is relatively low, it still attracts income-seeking investors.
- Shareholder Record Dates: The dividend will be payable on April 3, with a record date of March 24 and an ex-dividend date also on March 24, ensuring shareholders receive their dividends in a timely manner.
- Market Reaction Analysis: Although the dividend announcement did not significantly boost the stock price, the selling pressure on Heartland Express is viewed as logical, as the stock has reached a fully priced level, reflecting investor caution regarding future returns.
See More
Heartland Express Stock Surpasses Analyst Target Price
- Stock Performance: Heartland Express, Inc. (Ticker: HTLD) recently traded at $10.03 per share, surpassing the 12-month analyst target price of $10.00, indicating increased market confidence in the company.
- Analyst Reactions: When a stock reaches its target price, analysts may either downgrade their valuation or raise their target; currently, targets range from $8.00 to $12.00, with a standard deviation of $1.581, reflecting diverse market expectations.
- Investor Signal: The stock's rise above the target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is stretched or if further gains are possible.
- Wisdom of the Crowd: The average target price is derived from multiple analysts' opinions, and investors should pay attention to this
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
Analysis of Heartland Express Stock Performance
- Strong Stock Performance: Heartland Express has outperformed the S&P 500 by 19.7% over the past six months, with shares currently trading at $10.82, reflecting a 25.3% gain, which raises investor interest in its future performance.
- Disappointing Long-Term Revenue Growth: Despite short-term stock gains, Heartland Express has only achieved a 4.5% compounded annual growth rate over the past five years, falling short of the industrial sector benchmark, indicating a lack of long-term growth potential that may affect investor confidence.
- Declining Free Cash Flow: The company's free cash flow margin has dropped by 12.1 percentage points over the last five years, with a current margin of 7.8%, suggesting it may be in the middle of an investment cycle, raising concerns about future financial health.
- Decreasing Return on Invested Capital: Heartland Express has seen a significant decline in its return on invested capital (ROIC), indicating limited profitable growth opportunities, and combined with its already low returns, this may lead investors to question its future profitability.
See More
Heartland Express Reports Q4 Earnings with Declining EPS
- Earnings Report: Heartland Express reported a Q4 GAAP EPS of -$0.25, indicating challenges in profitability and reflecting a secular decline in returns on capital, which raises concerns about financial health.
- Revenue Figures: The company generated $179.4 million in revenue for the fourth quarter, which, while stable, suggests limited growth potential compared to industry benchmarks, potentially impacting future investment attractiveness.
- Growth Prospects: Analysts highlight that Heartland Express faces limited growth prospects; although risks appear to be priced in, the company must implement strategies to enhance its financial performance moving forward.
- Rating Analysis: According to Seeking Alpha's quant rating, Heartland Express's performance is under scrutiny, prompting investors to carefully assess its long-term investment value amidst the current financial challenges.
See More
Heartland Express Declares Quarterly Dividend of $0.02 per Share
- Quarterly Dividend Announcement: Heartland Express has declared a quarterly dividend of $0.02 per share, maintaining consistency with previous distributions, which demonstrates the company's ongoing ability to generate stable cash flow.
- Dividend Yield: The forward yield of 0.84% reflects the company's shareholder return strategy in the current market environment, indicating that while the yield is relatively low, it still attracts income-seeking investors.
- Shareholder Record Dates: The dividend will be payable on April 3, with a record date of March 24 and an ex-dividend date also on March 24, ensuring shareholders receive their dividends in a timely manner.
- Market Reaction Analysis: Although the dividend announcement did not significantly boost the stock price, the selling pressure on Heartland Express is viewed as logical, as the stock has reached a fully priced level, reflecting investor caution regarding future returns.
See More
Heartland Express Stock Surpasses Analyst Target Price
- Stock Performance: Heartland Express, Inc. (Ticker: HTLD) recently traded at $10.03 per share, surpassing the 12-month analyst target price of $10.00, indicating increased market confidence in the company.
- Analyst Reactions: When a stock reaches its target price, analysts may either downgrade their valuation or raise their target; currently, targets range from $8.00 to $12.00, with a standard deviation of $1.581, reflecting diverse market expectations.
- Investor Signal: The stock's rise above the target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is stretched or if further gains are possible.
- Wisdom of the Crowd: The average target price is derived from multiple analysts' opinions, and investors should pay attention to this
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
Analysis of Heartland Express Stock Performance
- Strong Stock Performance: Heartland Express has outperformed the S&P 500 by 19.7% over the past six months, with shares currently trading at $10.82, reflecting a 25.3% gain, which raises investor interest in its future performance.
- Disappointing Long-Term Revenue Growth: Despite short-term stock gains, Heartland Express has only achieved a 4.5% compounded annual growth rate over the past five years, falling short of the industrial sector benchmark, indicating a lack of long-term growth potential that may affect investor confidence.
- Declining Free Cash Flow: The company's free cash flow margin has dropped by 12.1 percentage points over the last five years, with a current margin of 7.8%, suggesting it may be in the middle of an investment cycle, raising concerns about future financial health.
- Decreasing Return on Invested Capital: Heartland Express has seen a significant decline in its return on invested capital (ROIC), indicating limited profitable growth opportunities, and combined with its already low returns, this may lead investors to question its future profitability.
See More
Heartland Express Reports Q4 Earnings with Declining EPS
- Earnings Report: Heartland Express reported a Q4 GAAP EPS of -$0.25, indicating challenges in profitability and reflecting a secular decline in returns on capital, which raises concerns about financial health.
- Revenue Figures: The company generated $179.4 million in revenue for the fourth quarter, which, while stable, suggests limited growth potential compared to industry benchmarks, potentially impacting future investment attractiveness.
- Growth Prospects: Analysts highlight that Heartland Express faces limited growth prospects; although risks appear to be priced in, the company must implement strategies to enhance its financial performance moving forward.
- Rating Analysis: According to Seeking Alpha's quant rating, Heartland Express's performance is under scrutiny, prompting investors to carefully assess its long-term investment value amidst the current financial challenges.
See More
